Article
Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma.
Oncogene - 1 Mar 2021
Schäfer Alexander, Haenig Benedicte, Erupathil Julie, Strickner Panja, Sabato Daniela, Welford Richard W D, Klaeylé Lhéanna, Simon Elise, Krepler Clemens, Brafford Patricia, Xiao Min, Herlyn Meenhard, Gstaiger Matthias, Lehembre Francois, Renz Imke
Abstract excerpt
The clinical benefit of MAPK pathway inhibition in melanoma patients carrying BRAF mutations is temporal. After the initial response to treatment, the majority of tumors will develop resistance and patients will relapse. Here we demonstrate that the endothelin-endothelin receptor B (ETBR) signaling pathway confers resistance to MAPK pathway inhibitors in BRAF mutated melanoma. MAPK blockade, in addition to being...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.